DIAGNOSTIC SERVICES

Heidelberg SPECTRALIS® OCT

Multi-modality imaging with SPECTRALIS is helping drive the development of novel therapeutics and changing the course of patient management in eye care. Using an upgradeable platform approach, SPECTRALIS has enhanced the role of spectral domain OCT by integrating it with confocal scanning laser ophthalmoscopy (cSLO). The combination of these two technologies has enabled new imaging capabilities, such as TruTrack™ active eye tracking and BluePeak™ blue laser autofluorescence, providing clinicians with unique views of the structure and function of the eye.

Video and Imaging Fluorescein and Indocyanine Green

The transition from static flash photography to dynamic video imaging opens up a new world of diagnostic detail and is especially helpful in recording the fill cycle. SPECTRALIS® FA can be combined with ICG angiography (ICGA), allowing the clinician to view both retinal and choroidal blood flow simultaneously. Clinicians can watch the dye coursing through the vessels and appreciate narrowing and partial blockage not always visible in static images.

Optos Retinal Imaging

The 200Tx device, designed specifically for general ophthalmologists and vitreoretinal specialists, offers multiple wavelength imaging including options for color, red-free, fluorescein angiography, and autofluorescence. With simultaneous non-contact pole-to-periphery views of more than 80%, or 200 degrees, of the retina in a single capture, the 200Tx helps clinicians discover more evidence of disease and guide their treatment decisions.

Fundus Autofluorescence (FAF)

BluePeak autofluorescence captures fundus autofluorescence (FAF) images, providing both structural and metabolic information about the retina. Without the need for dye, non-invasive BluePeak™ blue laser autofluorescence imaging takes advantage of the natural fluorescent properties of lipofuscin. Lipofuscin is a key component of RPE metabolism. Abnormal accumulation of lipofuscin is associated with many retinal diseases. Characteristic autofluorescence patterns seen in BluePeak images can reveal the extent of geographic atrophy (GA).

It can also assist clinicians in determining the diagnosis and management of hereditary conditions such as Best disease and Stargardt disease. BluePeak imaging is a clinical endpoint in studies of emerging therapeutics for GA and is becoming an essential tool in the management of degenerative diseases of the retina.

Ultrasonography

Utilizing both A-scan and B-scan ultrasound technology provides high definition quality images of the posterior segment of the eye, allowing the physician to diagnose and evaluate certain retinal diseases.